Comparison of the diagnostic performance of magnetic resonance elastography and Wisteria foribunda agglutinin‑positive Mac‑2‑binding protein in the determination of advanced liver fibrosis stages in patients with chronic liver disease

Wu,Kuan‑Lin; Chen,Yao‑Li; Ko,Chih‑Jan; Lin,Ping‑Yi; Chou,Chen‑Te

doi:10.3892/etm.2020.8922

Comparison of the diagnostic performance of magnetic resonance elastography and Wisteria foribunda agglutinin‑positive Mac‑2‑binding protein in the determination of advanced liver fibrosis stages in patients with chronic liver disease

Authors:
- Kuan‑Lin Wu
- Yao‑Li Chen
- Chih‑Jan Ko
- Ping‑Yi Lin
- Chen‑Te Chou
View Affiliations

Affiliations: Department of Diagnostic Radiology, Changhua Christian Hospital, Changhua 500209, Taiwan, R.O.C., Transplant Medicine and Surgery Research Center, Changhua Christian Hospital, Changhua 500209, Taiwan, R.O.C.
Published online on: June 22, 2020 https://doi.org/10.3892/etm.2020.8922
Pages: 1953-1960
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to compare the accuracy of Wisteria ﬂoribunda agglutinin-positive Mac-2-binding protein (WFA+‑M2BP) and magnetic resonance elastography (MRE) in determining the liver fibrosis stage in patients with chronic liver disease. A retrospective review of a prospectively maintained database was performed. The eligible patients had hepatic tumors and chronic liver disease, including hepatitis B (HBV) and HCV. All patients underwent blood sampling, MRE and hepatectomy at Changhua Christian Hospital (Changhua, Taiwan). Surgical specimens were used to determine definitive histopathological diagnoses and liver fibrosis stages. Measurement of liver stiffness was performed via MRI. The value of WFA+‑M2BP in each patient was also assessed. The area under the receiver operating characteristic (ROC) curve (AUC) was measured to compare the diagnostic accuracy of the two examinations. The results indicated that the serum WFA+‑M2BP levels were able to detect severe liver fibrosis (≥F3) in patients with chronic liver disease and performed as well as MRE in patients with HCV. Of the 238 patients enrolled in the present study, 135 had chronic HBV 75 had chronic HCV, 92 had early liver fibrosis (F1‑F2) and 139 patients had advanced liver fibrosis (F3‑F4). In predicting fibrosis stages ≥F3, MRE had an AUC of 0.89 with a cutoff value of 3.76 and serum WFA+‑M2BP had an AUC of 0.65 with a cutoff value of 1.32. MRE had higher AUCs than serum WFA+‑M2BP for predicting the severity based on the fibrosis stage in the total cohort and the HBV subgroup. In patients with HCV, no significant differences in diagnostic performance were identified between MRE and serum WFA+‑M2BP. In conclusion, determination of WFA+‑M2BP as a biomarker for predicting severe liver fibrosis (≥F3) is a reliable and non‑invasive method and performs as well as MRE in patients with chronic liver disease, particularly those with HCV.

View Figures

View References

1	Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D and Levine D: Elastography assessment of liver fibrosis: Society of radiologists in ultrasound consensus conference statement. Radiology. 276:845–861. 2015.PubMed/NCBI View Article : Google Scholar
2	Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet. 381:468–475. 2013.PubMed/NCBI View Article : Google Scholar
3	Bedossa P, Dargère D and Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 38:1449–1457. 2003.PubMed/NCBI View Article : Google Scholar
4	Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, Valasek MA, Aryafar H, Sirlin CB and Loomba R: Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. Hepatology. 63:453–461. 2016.PubMed/NCBI View Article : Google Scholar
5	Toshima T, Shirabe K, Takeishi K, Motomura T, Mano Y, Uchiyama H, Yoshizumi T, Soejima Y, Taketomi A and Maehara Y: New method for assessing liver fibrosis based on acoustic radiation force impulse: A special reference to the difference between right and left liver. J Gastroenterol. 46:705–711. 2011.PubMed/NCBI View Article : Google Scholar
6	Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, Kamada Y and Yoneda M: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis. J Gastroenterol Hepatol. 32:1922–1930. 2017.PubMed/NCBI View Article : Google Scholar
7	Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 24:289–293. 1996.PubMed/NCBI View Article : Google Scholar
8	Kuno A, Sato T, Shimazaki H, Unno S, Saitou K, Kiyohara K, Sogabe M, Tsuruno C, Takahama Y, Ikehara Y and Narimatsu H: Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl. 7:642–647. 2013.PubMed/NCBI View Article : Google Scholar
9	Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M and Narimatsu H: A serum ‘sweet-doughnut’ protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 3(1065)2013.PubMed/NCBI View Article : Google Scholar
10	DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 44:837–845. 1988.PubMed/NCBI
11	Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, Gotoh M, Narimatsu H, Korenaga M, Mizokami M, et al: A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 50:76–84. 2015.PubMed/NCBI View Article : Google Scholar
12	Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, et al: Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 50:776–784. 2015.PubMed/NCBI View Article : Google Scholar
13	Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, et al: Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res. 46:613–621. 2016.PubMed/NCBI View Article : Google Scholar
14	Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, Komatsu M, Matsumoto A, Ota M and Tanaka E: Serum wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 110:857–864. 2015.PubMed/NCBI View Article : Google Scholar
15	Yamada N, Sanada Y, Tashiro M, Hirata Y, Okada N, Ihara Y, Urahashi T and Mizuta K: Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J Gastroenterol. 52:245–252. 2017.PubMed/NCBI View Article : Google Scholar
16	Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, et al: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: A comparative study. J Viral Hepat. 23:977–984. 2016.PubMed/NCBI View Article : Google Scholar
17	Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH: AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63:261–283. 2016.PubMed/NCBI View Article : Google Scholar
18	Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O and Yano M: Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies. Hepatology. 25:1028–1031. 1997.PubMed/NCBI View Article : Google Scholar
19	McMahon BJ: The natural history of chronic hepatitis B virus infection. Hepatology. 49 (Suppl 5):S45–S55. 2009.PubMed/NCBI View Article : Google Scholar
20	Bedossa P: Reversibility of hepatitis B virus cirrhosis after therapy: Who and why? Liver Int. 35 (Suppl 1):S78–S81. 2015.PubMed/NCBI View Article : Google Scholar
21	AASLD/IDSA HCV Guidance Panel: Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62: 932-954, 2015.